Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Measles and Rubella Vaccine (PT Bio Farma)
- Development stage
- Phase 4
- Lead developer
- Bio Farma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The Measles-Rubella (MR) vaccine by PT Bio Farma is a live attenuated viral vaccine indicated for the active immunization of infants and children against measles and rubella infections. It is a critical component of the Indonesian National Program of Immunization and has achieved WHO prequalification, enabling its distribution through international agencies such as UNICEF and PAHO. The vaccine contains live attenuated strains of the measles virus (typically Edmonston-Zagreb) and rubella virus (typically Wistar RA 27/3), which stimulate the immune system to produce protective antibodies and activate cellular immunity. Administered via subcutaneous injection, it is used to prevent measles, rubella, and congenital rubella syndrome (CRS). PT Bio Farma is the sole local vaccine manufacturer in Indonesia and produces this vaccine to meet both domestic and international public health needs.
- Brand names
- Vaksin MR Bio Farma
- Other names
- MR VaccineMeasles-Rubella VaccineVaksin Campak-Rubella
Beyond the preview
Go deeper on Measles and Rubella Vaccine (PT Bio Farma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Measles and Rubella Vaccine (PT Bio Farma).